Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab - Test2 - elhamkhani - TriplyDB

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

http://www.wikidata.org/entity/Q24600031

about

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Markers of resistance to anti-EGFR therapy in colorectal cancer Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Kirsten Ras* oncogene: Significance of its discovery in human cancer research Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS Pharmacologic resistance in colorectal cancer: a review The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy Role of HER2 in NSCLC Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Personalized treatment for advanced colorectal cancer: KRAS and beyond Targeting of erbB3 receptor to overcome resistance in cancer treatment Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies Acquired resistance to EGFR-targeted therapies in colorectal cancer HER2 as a therapeutic target in head and neck squamous cell carcinoma CIViC database An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.HER2 activating mutations are targets for colorectal cancer treatment Beyond RAS and BRAF: a target rich disease that is ripe for picking Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion A perspective on anti-EGFR therapies targeting triple-negative breast cancer Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence Clinical applications of liquid biopsies in gastrointestinal oncology Mechanisms of resistance to anti-EGFR therapy in colorectal cancer RAS and BRAF in metastatic colorectal cancer management Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis Cytohesins/ARNO: the function in colorectal cancer cells Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

P2860

d6622bec24a27184e0c53206e9c0b7dc329b179b

P248

Q24563539-5B5F4157-B7D1-401F-BA0C-BE3A8461756E Q24598640-B7DDE60C-2D70-4B76-BB72-55571BFA768D Q24604601-365A02DD-E9BF-4DDE-B50C-AF3ACCDC8B12 Q26748924-DAABE183-D594-4091-8EFC-09100247EFEE Q26751212-126A3792-3AFD-4304-A1DC-F8FD65018910 Q26751344-496FB28D-6087-44DB-BB34-4EA43B2B5936 Q26766535-92D91456-C024-43DB-939E-1B79299212AA Q26769850-42FDE688-851D-4638-83F4-FFF70B0C1124 Q26777125-DD436251-3444-4F50-AEDB-7BCE8C37FA18 Q26781683-5FCACA76-ABA5-4ED6-85C9-CC29817839E1 Q26782809-D6A99E93-C29A-48C8-A749-6265C9D2427A Q26796348-67834AB2-46DB-4F2B-9CBA-E2D9A8078DBC Q26822817-FB7A9423-A7E0-4B71-861B-72B2BD5C57F1 Q26864668-7C4DBB56-0260-48E0-8724-E7D79E26FE8D Q26991953-E0A3AEF1-F5AC-4DD9-BB0C-9155DDB03F61 Q27015224-36A17D86-3CE8-47AC-AADF-84CB84DE4CAF Q27022741-2F24D035-3894-40C0-BBCE-877BD235EED1 Q27026178-5A1804C7-C60A-4A5B-9588-CF9A3F5BCD07 Q27612411-1B7F69B9-1DEE-4E2E-949E-4C2412AA5BE7 Q27679463-3B2AD78B-2326-4A2D-BBA2-564C6AE8F702 Q27687709-E252A7A3-9A1B-4305-ADDF-6494DA4FB09E Q27852057-30FDBF5A-E1D0-4C91-81B3-994CA2FE7C7C Q27853193-AD2BE9A6-BEFA-48E6-A010-1DCBFB254203 Q28066095-767A3756-EEF6-41B3-B390-0831A4D4A5CF Q28066285-92ADF586-24C9-4036-B67F-1024D631D79C Q28069867-E48DB02C-07FF-4784-9365-D00E3CE56D26 Q28071772-58B3452D-EBCE-4847-91E8-7A50D7509B67 Q28073730-139DA74A-A526-497E-B17A-D8777679AAA5 Q28074073-16FCE8EB-8184-4400-B604-934673D7DABF Q28074175-92A78D7C-8098-4B87-A3FF-E7E35E28B65C Q28076490-9B74643A-87B3-410F-B4D0-933BA9F601C0 Q28077545-04EDA5DA-5F2C-467C-8ED8-2264B7B4F6EA Q28285473-8DE6801A-57D3-4054-AEB2-9A61CDB50454 Q28468648-CF7C8EFC-E277-4AD8-8BB7-19977AAFCAA3 Q28540108-821B65A1-ADEC-46E3-A9E5-6929F2DCC46B Q28540770-86BDC98B-02C3-4C4E-9F02-02432718882F Q28553202-D28E86BF-53C3-4C83-BA83-1CE7919A509F Q29395525-66D9BB9D-C14A-4D73-9A69-40D16D8CC453 Q30379025-C3C69B28-82E5-4034-8EDC-6A1BC6348EBB Q33601653-A5B7DD1B-9132-4525-9F07-E75CDF9399D9

P2860

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

http://www.wikidata.org/entity/Q24600031

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@ast

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@en

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@nl

type

label

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@ast

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@en

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@nl

altLabel

Activation of ERBB2 Signaling ...... Therapeutic Antibody Cetuximab

@en

prefLabel

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@ast

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@en

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@nl

P1433

Q24600031-AF6819E3-5812-499C-B163-DBDA1BB15CE4

P1476

Q24600031-6C7D0F76-871E-44C9-830D-7398ACDA6C24

P2093

Q24600031-068DBB08-D6D4-4780-AF90-3D7817A11BEC

Q24600031-2A88C418-8F57-4733-94E8-01F98C7BA049

Q24600031-326D8357-944C-43A5-BAF1-8B5C6BF8681B

Q24600031-366B191C-9672-4AED-891B-7E1E089F860D

Q24600031-42C74116-5611-4CDF-B9E2-844B8E7DFD03

Q24600031-51F8EEF9-4F79-4AA8-8DDE-9F5C60E47446

Q24600031-5252020A-A599-4ED5-83C9-876F82B942D6

Q24600031-531DE74B-E72C-4948-849D-A33FEAF66F56

Q24600031-55E27B44-ADC4-4B75-BCA9-ECEF01FCA870

Q24600031-61A4DB2D-2273-4867-AD04-D394CBE0AE4E

P2860

Q24600031-04E0D363-C1B4-45A9-923B-2F94C7DBCC5F

Q24600031-05DDFDED-77E1-497D-98D4-9B199E7E5DB6

Q24600031-07381C57-494C-49D2-AE2D-6E9BB672BF0E

Q24600031-0FBE6E4C-3B90-4CD0-AE79-86084C13839A

Q24600031-160B55FF-33D3-44A0-9997-C1EECDBDF70B

Q24600031-189EFF6C-AA9F-400D-BFD9-CE7A5ACDD45C

Q24600031-1F1C00D2-EC26-4156-BB39-528C84F8F04E

Q24600031-276DE296-C732-439E-9734-06C05330633C

Q24600031-2F719C1D-FA6C-454B-8ED9-7A13F52162D4

Q24600031-32C13588-394E-4C69-A81A-3C3062CF349D

P304

Q24600031-D75996A6-1B7B-4B26-8546-ED4B5CFAA1D3

P31

Q24600031-61B38024-3EDD-4C59-930B-3C535A301166

P3181

Q24600031-AF2683F7-379E-40C4-B65E-267840F4CA81

P356

Q24600031-F9CB0E77-B0AC-427F-9A6D-8D9FCAB76746

P407

Q24600031-F93FBC36-E8EC-4A1F-BB7E-3E96E59E2055

P433

Q24600031-52FB9848-2A54-48D4-8A72-D382A0F72B74

P478

Q24600031-858CD6EE-A141-47E0-B3B3-ABE5E76BF66F

P50

Q24600031-2223CCA0-E548-4B23-A7F8-BD8324A7AA4F

Q24600031-6ECF368F-70B3-4EEB-9767-D0A41A2DACF4

P577

Q24600031-BC196FCE-1CD3-44D9-8BAE-0FB44A4845C7

P5875

Q24600031-8BFF332F-BE74-4197-A99E-99CF551DE37B

P698

Q24600031-5BA8557F-0926-4FBD-A5B7-980E61E9DA67

P921

Q24600031-2A07185F-E5C9-4D17-94B7-6220A8CF1949

Q24600031-59F9B331-DD5E-45D0-9714-A924A8B1DF2E

P932

Q24600031-E8D2FE9D-FF82-4F61-B335-AF96152A27C1

P3181

P356

SCITRANSLMED.3002442

P1433

Science Translational Medicine

P1476

Activation of ERBB2 signaling ...... therapeutic antibody cetuximab

@en

P2093

Andrew Rogers

http://www.w3.org/2001/XMLSchema#string

Annarita Destro

http://www.w3.org/2001/XMLSchema#string

Dalia Ercan

http://www.w3.org/2001/XMLSchema#string

Eugene Lifshits

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Itoh

http://www.w3.org/2001/XMLSchema#string

Isamu Okamoto

http://www.w3.org/2001/XMLSchema#string

Jason Sun

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Jeffrey Swanson

http://www.w3.org/2001/XMLSchema#string

John Souglakos

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

P304

99ra86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

254073

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCITRANSLMED.3002442

http://www.w3.org/2001/XMLSchema#string

P407

P433

99

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Federico Cappuzzo

Massimo Roncalli

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51626543

http://www.w3.org/2001/XMLSchema#string

P698

21900593

http://www.w3.org/2001/XMLSchema#string

P921

P932

3268675

http://www.w3.org/2001/XMLSchema#string